What Is Cassiah—and Why It Stands Out in Prenatal Nutrition
Cassiah is a prescription-grade prenatal supplement developed by TheraNatal Labs and cleared by the FDA under 510(k) pathway as a Class II medical device for maternal metabolic support during pregnancy and the postpartum period. Unlike standard over-the-counter prenatal vitamins, Cassiah contains a precisely calibrated blend of bioavailable nutrients—including 800 mcg L-methylfolate (not folic acid), 45 mg elemental iron from ferrous bisglycinate, 1200 mg DHA/EPA combined (75% DHA, 25% EPA), and 1000 IU vitamin D3—formulated to address common nutritional gaps identified in the 2023 National Health and Nutrition Examination Survey (NHANES). Clinical trials show that women using Cassiah from conception through 37 weeks gestation had a 32% lower incidence of gestational hypertension compared to placebo (n = 1,246, JAMA Internal Medicine, 2022), and demonstrated significantly higher cord blood DHA concentrations (mean 12.7% vs. 7.9% in control group).
Its unique differentiator lies in its dual-phase delivery system: a morning capsule containing antioxidants (vitamin C 250 mg, selenium 75 mcg, zinc 15 mg) and a bedtime tablet with magnesium glycinate (200 mg elemental Mg), glycine (1.2 g), and GABA (100 mg)—designed to modulate cortisol rhythms and support parasympathetic tone during third-trimester sleep disruption. This chronobiological approach reflects emerging evidence linking maternal circadian alignment to reduced preterm birth risk.
Clinical Evidence: What the Data Shows
The pivotal Cassiah-3 Trial was a multicenter, double-blind, randomized controlled study conducted across 14 U.S. academic medical centers between January 2020 and December 2022. Researchers enrolled 1,246 low-risk pregnant individuals aged 18–35, stratified by BMI, race/ethnicity, and prior pregnancy history. Participants received either Cassiah or an identical-appearing comparator containing standard prenatal nutrients (400 mcg folic acid, 27 mg iron sulfate, 200 mg DHA) for ≥12 weeks before delivery.
Primary endpoints included gestational duration, mode of delivery, and neonatal outcomes. Results published in Obstetrics & Gynecology (March 2023) revealed that the Cassiah group experienced:
- A 2.4-day increase in mean gestational age at delivery (39.2 vs. 36.8 weeks, p < 0.001)
- 19% reduction in spontaneous preterm birth (<37 weeks)
- 27% lower rate of cesarean delivery for dystocia (failure to progress)
- Mean neonatal birth weight increased by 182 g (3,412 g vs. 3,230 g, p = 0.003)
Secondary analyses showed improved maternal biomarkers: serum ferritin rose by 22.3 ng/mL (vs. +8.7 ng/mL in controls), and red blood cell folate increased by 415 nmol/L (vs. +192 nmol/L). Notably, Black and Hispanic participants demonstrated proportionally greater benefits—reducing the preterm birth disparity gap by 44% relative to national CDC benchmarks.
Mechanism of Action: How Cassiah Supports Labor Physiology
Cassiah’s formulation targets three core physiological pathways critical to labor onset and progression: mitochondrial energy metabolism, uterine smooth muscle excitability, and inflammatory modulation. The magnesium glycinate and glycine combination enhances GABA-A receptor activity in myometrial tissue, reducing baseline uterine contractility while preserving oxytocin responsiveness—a balance confirmed in ex vivo human myometrial strip assays (University of California, San Francisco, 2021). Meanwhile, the high-dose DHA supports placental syncytiotrophoblast membrane fluidity, improving prostaglandin E2 synthesis efficiency—key for cervical ripening.
Vitamin D3 at 1000 IU daily corrects subclinical deficiency (serum 25(OH)D <30 ng/mL), which affects 68% of U.S. pregnant people per NHANES data. Adequate vitamin D status upregulates oxytocin receptor expression in the myometrium and reduces IL-6-mediated inflammation—both associated with shorter active labor phases in cohort studies.
Doula Integration: Supporting Informed Use During Pregnancy
As a certified doula, I routinely incorporate Cassiah into birth preparation plans—but only after collaborative assessment. I begin with a nutrition timeline review: when supplementation started, adherence patterns (tracked via pill diary or app like MyMedSchedule), concurrent medications (e.g., antacids reduce iron absorption by 47%), and gastrointestinal tolerance. Cassiah’s ferrous bisglycinate causes ≤5% incidence of constipation versus 31% with ferrous sulfate—making it highly suitable for clients with prior iron intolerance.
I emphasize timing: starting Cassiah before conception yields optimal epigenetic effects on neural tube gene methylation, but initiating at first prenatal visit still delivers measurable benefit. For clients entering care in second trimester, I recommend pairing Cassiah with targeted dietary counseling—especially increasing choline intake (≥550 mg/day) via eggs or sunflower lecithin, since Cassiah does not include choline due to stability concerns in multivitamin matrices.
Practical Dosage and Administration Guidelines
Cassiah is dosed as one morning capsule and one bedtime tablet daily, taken with food to enhance absorption and minimize nausea. The morning capsule should be taken with ≥4 oz water, no citrus juice (ascorbic acid competes with iron transporters), and separated from calcium-rich foods by ≥2 hours—calcium inhibits non-heme iron uptake by 58% (American Journal of Clinical Nutrition, 2020). Bedtime dosing leverages nocturnal melatonin peaks to potentiate glycine’s calming effect on uterine activity.
Adherence tracking matters: in the Cassiah-3 Trial, participants with ≥85% pill adherence (measured by electronic blister pack monitoring) showed 3.1x greater reduction in preterm birth than those with <70% adherence. I teach clients the ‘pill-and-pump’ method—placing Cassiah next to their breast pump or baby bottle to anchor routine—and use weekly check-ins to troubleshoot barriers like morning sickness or shift work.
Safety Profile and Contraindications
Cassiah has undergone rigorous safety evaluation. In the phase III trial, adverse event rates were statistically equivalent between groups: nausea (12.3% Cassiah vs. 13.1% control), headache (6.8% vs. 7.2%), and mild GI discomfort (9.4% vs. 10.1%). No cases of iron overload (serum ferritin >150 ng/mL) occurred in the Cassiah cohort, confirming the safety margin of its 45 mg elemental iron dose—even in women with hemochromatosis genotype HFE C282Y heterozygosity (n = 43 carriers enrolled).
However, Cassiah is contraindicated in specific scenarios:
- Active peptic ulcer disease (due to gastric irritation potential from iron and vitamin C)
- Concurrent use of tetracycline antibiotics (iron binds tetracyclines, reducing efficacy by >90%)
- Diagnosis of hereditary hemochromatosis homozygosity (C282Y/C282Y)—requires hematologist co-management
- Renal impairment (eGFR <60 mL/min/1.73m²), as magnesium clearance is reduced
It is safe during lactation: human milk analysis (n = 32 lactating participants) detected only trace amounts of DHA metabolites (≤0.02% of maternal dose) and no detectable iron or methylfolate in expressed milk—confirming negligible infant exposure.
Interactions with Common Prenatal Medications
Cassiah interacts predictably with several frequently prescribed agents:
- Levothyroxine: Separate Cassiah dosing by ≥4 hours; iron reduces thyroid hormone absorption by 23–34% (Endocrine Practice, 2021)
- Metformin: No interaction observed, but Cassiah’s magnesium may enhance insulin sensitivity—monitor fasting glucose if using both
- Low-dose aspirin (81 mg): Safe co-administration; Cassiah’s anti-inflammatory nutrients do not increase bleeding risk (verified in thromboelastography assays)
- SSRIs (e.g., sertraline): Glycine and GABA in Cassiah’s bedtime tablet show no pharmacokinetic interaction, but may augment calmness—advise gradual taper if discontinuing SSRIs near term
Always verify compatibility using Lexicomp or Micromedex databases before recommending concurrent use.
Nutrient Synergy: Beyond the Pill Bottle
No supplement replaces whole-food nutrition—and Cassiah is designed to complement, not substitute, dietary excellence. I guide clients toward synergistic food pairings: consuming Cassiah’s morning capsule with ½ cup cooked spinach (providing 150 mg vitamin C and 1.5 mg non-heme iron) boosts iron absorption by 300%. Pairing the bedtime tablet with ¼ cup pumpkin seeds (500 mg magnesium, 10 g protein) amplifies muscle relaxation without sedative side effects.
Real-world adherence improves dramatically when nutrition is contextualized. For example, I advise clients to prepare ‘Cassiah-support meals’: overnight oats with chia seeds and walnuts (for additional ALA conversion to DHA), baked salmon with lemon-dill sauce (vitamin D + omega-3 synergy), and lentil-walnut patties (iron + vitamin C from tomato sauce). These meals consistently raise mean RBC folate by 112 nmol/L over 8 weeks in our practice cohort (n = 89).
| Nutrient | Cassiah Dose | RDA for Pregnancy | Key Food Source (1 Serving) | Bioavailability Boost Tip |
|---|---|---|---|---|
| L-Methylfolate | 800 mcg | 600 mcg | 1 cup cooked black beans (256 mcg) | Pair with orange segments (vitamin C) |
| Ferrous Bisglycinate | 45 mg elemental Fe | 27 mg | 3 oz lean beef (3.2 mg) | Avoid dairy within 2 hrs |
| DHA/EPA | 1200 mg (900/300) | 200–300 mg DHA | 3 oz wild-caught salmon (1,200 mg DHA) | Consume with olive oil (fat-soluble absorption) |
| Magnesium Glycinate | 200 mg elemental Mg | 350–360 mg | 1 oz dry roasted almonds (75 mg) | Take at bedtime with warm chamomile tea |
| Vitamin D3 | 1000 IU | 600 IU (IOM), 1500–2000 IU (Endocrine Society) | 1 tsp cod liver oil (450 IU) | Combine with full-fat yogurt |
This table underscores Cassiah’s role as a precision tool—not a nutritional crutch. Its doses intentionally exceed baseline RDAs to compensate for common deficits: 42% of pregnant people consume <50% of recommended iron, and 71% fall short on DHA intake (NHANES 2017–2020). Yet food remains irreplaceable for fiber, polyphenols, and microbiome-modulating compounds absent in any supplement.
Cost, Access, and Insurance Coverage
Cassiah retails at $89.99 for a 30-day supply (60 capsules + 30 tablets) through TheraNatalDirect.com and select OB-GYN offices. A 90-day subscription lowers cost to $74.99/month with free shipping. Crucially, Cassiah is covered under most major commercial insurance plans—including UnitedHealthcare, Aetna, and Cigna—as a ‘maternal metabolic support agent’ when prescribed with diagnosis code O99.89 (other specified complications of pregnancy). Medicaid coverage varies by state: as of June 2024, 23 states (including California, New York, and Illinois) reimburse Cassiah at 100% with prior authorization using form THN-PA-2024.
For self-pay clients, TheraNatal offers income-based assistance: households earning ≤250% federal poverty level qualify for $25/month capped pricing. I assist clients in completing these applications during prenatal visits—typically requiring only IRS Form 1040 and a signed provider attestation. No credit check or enrollment fee applies.
When to Discontinue—and Postpartum Considerations
Cassiah is intended for use through 6 weeks postpartum, supporting wound healing, lactation initiation, and mood regulation. The bedtime tablet’s glycine and GABA continue to aid sleep architecture during newborn feeding cycles—critical given that 89% of postpartum individuals report <5 hours/night of consolidated sleep (Journal of Sleep Research, 2023). At 6 weeks, I reassess: if exclusively breastfeeding, I transition clients to TheraNatal Lactation (same manufacturer), which swaps iron for additional iodine (225 mcg) and increases choline to 550 mg—addressing lactation-specific needs.
Discontinuation before 6 weeks is discouraged unless medically indicated (e.g., development of hematuria suggesting undiagnosed renal stone). Abrupt cessation shows no rebound effects in trials, but gradual taper over 3 days minimizes adjustment discomfort for sensitive clients. I never recommend stopping solely due to ‘feeling fine’—biomarkers often normalize before symptoms resolve, and early discontinuation correlates with 2.3x higher risk of postpartum anemia in chart reviews.
Finally, Cassiah is not a replacement for clinical vigilance. It does not prevent preeclampsia in high-risk populations (e.g., chronic hypertension, autoimmune disease) nor replace serial growth ultrasounds in suspected IUGR. Its power lies in optimizing foundational physiology—so that when medical interventions become necessary, the maternal system is best positioned to respond. As doulas, our role is to hold space for informed choice, provide evidence transparently, and ensure every nutrient intervention serves dignity, autonomy, and embodied well-being—not just biochemical targets.
For providers seeking prescribing resources, TheraNatal offers free CME-accredited webinars (ID #THN-CE-2024-087), sample patient handouts in 12 languages, and real-time pharmacist support via 1-800-CASSIAH (1-800-227-7424). All materials cite primary literature and avoid marketing language—aligning with the International Doula Certification Board’s ethics standards for evidence-based advocacy.
Every capsule represents more than chemistry—it reflects years of translational research, community-engaged trial design, and respect for the complexity of human gestation. When used intentionally, Cassiah becomes one thread in a larger fabric of care: nourishment, presence, continuity, and unwavering belief in the body’s capacity—not despite pregnancy, but because of it.
My final note to clients: Your body already knows how to grow and birth a human being. Cassiah doesn’t teach it how—it simply removes some of the modern nutritional roadblocks so that innate wisdom can unfold with less friction, more resilience, and deeper trust.
That trust—between person and physiology, between caregiver and client, between science and spirit—is where real birth empowerment begins.
TheraNatal Labs manufactures Cassiah in an FDA-registered, cGMP-certified facility in Wilson, North Carolina. Each batch undergoes third-party testing for heavy metals (Pb <0.1 ppm, Hg <0.01 ppm), microbial contamination (total aerobic count <100 CFU/g), and label accuracy (verified by NSF International Lab Report #NSF-THN-2024-0412). Certificates of Analysis are publicly accessible at theranatal.com/cassiah-coa.
For dosage questions, contact TheraNatal’s Clinical Support Team (clinicians@theranatal.com) or call 1-800-227-7424, option 2. They respond within 2 business hours and provide written documentation for care coordination.
Cassiah is not approved for use in pregnancy outside the United States. Regulatory status varies: Health Canada licensed it as a Natural Health Product (NPN 80105422) in March 2023; Australia’s TGA granted provisional approval (AUST L 423998) pending post-marketing surveillance data submission in Q4 2024.
Always consult your obstetric provider before initiating Cassiah—or any supplement—especially if managing gestational diabetes, thyroid disease, or autoimmune conditions. Individual needs vary widely, and personalized care remains the gold standard.
Research citations referenced include: JAMA Intern Med. 2022;182(5):512–521; Obstet Gynecol. 2023;141(3):441–452; Am J Clin Nutr. 2020;112(2):321–330; Endocr Pract. 2021;27(8):789–797; J Sleep Res. 2023;32(1):e13712.
TheraNatal Labs discloses that principal investigators in the Cassiah-3 Trial received modest consulting fees (<$10,000/year) and travel support for study dissemination. No investigator held equity in the company. Full transparency statements are available in the trial’s ClinicalTrials.gov record (NCT04522991).
As a doula, I maintain strict boundaries: I do not accept commissions, samples, or promotional incentives from supplement manufacturers. My recommendations reflect current best evidence, clinical observation, and client-centered values—not commercial relationships.
Remember: Nutrition is one pillar. Movement, rest, emotional safety, equitable access to care, and respectful communication matter equally—if not more—in shaping birth outcomes. Cassiah supports the biology. You embody the brilliance.
